Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3171/jns.1968.28.6.0560 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.
Int J Pharm X
December 2022
EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France.
Chemoresistance and hence the consequent treatment failure is considerably challenging in clinical cancer therapeutics. The understanding of the genetic variations in chemoresistance acquisition encouraged the use of gene modulatory approaches to restore anti-cancer drug efficacy. Many smart nanoparticles are designed and optimized to mediate combinational therapy between nucleic acid and anti-cancer drugs.
View Article and Find Full Text PDFProspective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide.
Cureus
April 2022
Orthopaedics, University of Minnesota, Minneapolis, USA.
Pegylated liposomal doxorubicin (PLD) is widely used and can be used for prolonged periods, with the limiting toxicity usually being hand-foot syndrome (HFS). The pharmacokinetics of PLD is variable between patients, leading to variability in the risk of developing HFS. Dosing based on body surface area does not decrease variability in PLD clearance; thus, other predictive markers could be useful.
View Article and Find Full Text PDFBiological drug and drug delivery-mediated immunotherapy.
Acta Pharm Sin B
April 2021
Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
The initiation and development of major inflammatory diseases, , cancer, vascular inflammation, and some autoimmune diseases are closely linked to the immune system. Biologics-based immunotherapy is exerting a critical role against these diseases, whereas the usage of the immunomodulators is always limited by various factors such as susceptibility to digestion by enzymes , poor penetration across biological barriers, and rapid clearance by the reticuloendothelial system. Drug delivery strategies are potent to promote their delivery.
View Article and Find Full Text PDFIncidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States.
Clin Lymphoma Myeloma Leuk
July 2019
Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address:
Background: Limited knowledge exists on the incidence, treatment patterns, and long-term outcomes of Langerhans cell sarcoma (LCS) in the United States.
Patients And Methods: We performed a retrospective study of LCS patients diagnosed between 2001 and 2014 using the Surveillance, Epidemiology, and End Results (SEER) and National Cancer Data Base (NCDB) databases. Incidence was calculated from SEER, and treatment patterns and outcomes were calculated from NCDB.
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
J Bone Oncol
June 2019
Academic Orthopaedic Unit, Papageorgiou General Hospital, Aristotle University Medical School, West Ring Road of Thessaloniki, Pavlos Melas Area, N. Efkarpia, 56403 Thessaloniki, Greece.
Over the past few decades, there has been growing interest in understanding the molecular mechanisms of cancer pathogenesis and progression, as it is still associated with high morbidity and mortality. Current management of large bone sarcomas typically includes the complex therapeutic approach of limb salvage or sacrifice combined with pre- and postoperative multidrug chemotherapy and/or radiotherapy, and is still associated with high recurrence rates. The development of cellular strategies against specific characteristics of tumour cells appears to be promising, as they can target cancer cells selectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!